(MedPage Today) — DENVER — Two therapeutic candidates for severe hidradenitis suppurativa (HS) achieved major responses that proved durable in randomized trials reported here.
The IL-17A/F inhibitor sonelokimab achieved at least 75% skin clearance…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
